Breaking News
December 14, 2017 - Living Lyme disease bacteria found months after antibiotic treatment
December 14, 2017 - These annual checkups help seniors not only survive but thrive
December 14, 2017 - Study reveals impact of diabetes during pregnancy on baby’s heart
December 14, 2017 - Huntington’s disease drug clears initial hurdles
December 14, 2017 - TPU researchers create 3D-printed models of children’s hearts
December 14, 2017 - Brain responses of children with inherited dyslexia risk predict their future reading speed
December 14, 2017 - Study: New Furosemide Formulation Simplifies Administration for HF
December 14, 2017 - Discrimination harms your health—and your partner’s
December 14, 2017 - Having older brothers may increase the likelihood of being gay
December 14, 2017 - New scientific yardstick released to help early detection of Alzheimer’s disease
December 14, 2017 - New finding demonstrates what happens at cellular level during onset of type2 diabetes
December 14, 2017 - Study identifies potassium as key to circadian rhythms in red blood cells
December 14, 2017 - NIH expected to award up to $70 million to launch Alzheimer’s Clinical Trials Consortium
December 14, 2017 - Pitting pathogens against each other could prevent drug resistance emerging
December 14, 2017 - Study provides new insights into development of Sonic Hedgehog medulloblastoma
December 14, 2017 - Dr. Reddy’s Announces Approval of Impoyz (clobetasol propionate) Cream for Plaque Psoriasis
December 14, 2017 - Gene Screens Can Alter Perception, Behavior
December 14, 2017 - Can Scrotal Vein Condition Hike Heart Risks?: MedlinePlus Health News
December 14, 2017 - Molecules in spit may be able to diagnose and predict length of concussions
December 14, 2017 - Children’s Colorado and RxRevu partner to help prescribers better meet needs of pediatric patients
December 14, 2017 - Researchers discover new way to attack drug-resistant prostate cancer cells
December 14, 2017 - Scientists develop new, high resolution method for identifying microbial species and strains
December 14, 2017 - Declining trend of salmonellosis cases has leveled off in the EU
December 14, 2017 - Death receptors in the blood can help measure risk of cardiovascular diseases, type 2 diabetes
December 14, 2017 - How to Perk Up the Holidays for Hospital Patients
December 14, 2017 - Prolonged Sedation May be Bad for Baby’s Brain
December 14, 2017 - The pediatric submersion score predicts children at low risk for injury following submersions
December 14, 2017 - Video game helps doctors to quickly recognize trauma patients who need high levels of care
December 14, 2017 - Younger persons newly-diagnosed with type 2 diabetes have poorer health than older patients
December 14, 2017 - Clinician re-examines evidence on re-use of catheters and UTIs in people with spinal cord injuries
December 14, 2017 - UK and Russian researchers join forces against AMR
December 14, 2017 - Results of Bariatric Surgery Hold Up Over Time
December 14, 2017 - High-intensity exercise delays Parkinson’s progression
December 14, 2017 - Protein structure could pave way for effective drugs to treat cystic fibrosis
December 14, 2017 - Minority people less likely to see dermatologist for psoriasis treatment
December 14, 2017 - Study indicates decline in use of chemotherapy for early stage breast cancer patients
December 14, 2017 - Chagas disease presents real public health problem to Canadians
December 14, 2017 - Experts call for rigorous clinical trials in use of experimental fetal therapy
December 14, 2017 - Lactic acid bacteria can offer protection against subtypes of influenza A virus
December 14, 2017 - Tapeworm drug could provide new hope for patients with Parkinson’s disease
December 14, 2017 - Parkinson’s progression delayed through high-intensity exercise, study says
December 14, 2017 - Researchers discover potential regulator essential for killer T cells to reside in tumors
December 14, 2017 - Tailor-made protein combats several kinds of pathogenic bacteria
December 14, 2017 - Hidden genes hold blueprints for designing new anti-cancer drugs
December 14, 2017 - Male virgins still at risk for acquiring HPV, study finds
December 14, 2017 - Study reveals novel molecular targets to improve chemotherapy’s efficiency against leukemia
December 14, 2017 - Talazoparib Significantly Extends Progression-Free Survival in Phase 3 EMBRACA Trial of Patients with Metastatic Breast Cancer
December 14, 2017 - AHA: Hospital QI Initiative Fails to Budge Outcomes in India
December 14, 2017 - Scientists observe tremors associated with Parkinson’s disease in fruit flies
December 14, 2017 - Newly discovered molecular chaperones may soon be part of therapies for Huntington’s disease
December 14, 2017 - Performing surgery on virtual patient could provide valuable insight into consequences
December 13, 2017 - New insights into mosquito sex protein could provide strategies to control diseases
December 13, 2017 - Lilly’s Taltz (ixekizumab) Receives U.S. FDA Approval for the Treatment of Active Psoriatic Arthritis
December 13, 2017 - Step Into Sunshine | Medpage Today
December 13, 2017 - Poor Prognosis for Diabetic Foot Sores: MedlinePlus Health News
December 13, 2017 - Exercise alone does not lead to weight loss in women—in the medium term
December 13, 2017 - Researchers use new approach to identify casual mechanisms in depression
December 13, 2017 - Genetic Analysis and Bio-Rad enter into supply and distribution agreement for GA-map clinical test
December 13, 2017 - Study finds barriers to stem cell transplant use among multiple myeloma patients from minority groups
December 13, 2017 - Scientists discover how axons in developing visual system stabilize their connections
December 13, 2017 - Novel compound inhibits mycomembrane biosynthesis and kills tuberculosis bacteria
December 13, 2017 - FDA Launches New Tool for Sharing Information That Allows Doctors to Better Manage Antibiotic Use
December 13, 2017 - Evolocumab Wins FDA Approval for Stand-Alone CVD Prevention
December 13, 2017 - Powerful Clot-Busting Drugs Not Useful After Leg Blockages: Study: MedlinePlus Health News
December 13, 2017 - The fight against obesity: To tax or not to tax?
December 13, 2017 - Isolation during holidays can impact health of seniors
December 13, 2017 - Specialized physiotherapy provides many benefits for patients with Parkinson’s disease
December 13, 2017 - Pairing immunotherapy drug with chemotherapy proves beneficial for relapsed acute myeloid leukemia
December 13, 2017 - Researchers find link between brain structure and hallucination proneness, musical aptitude
December 13, 2017 - Radiation responsive molecules derived from horse chestnuts aid cancer imaging
December 13, 2017 - New Gene Therapy May Be Cure for ‘Bubble Boy’ Disease
December 13, 2017 - MorningBreak: Insurance Driving Drug Prices? Crunch Time for ACA; The ‘Other’ Drug Problem
December 13, 2017 - Are Stents Really Useless After Chest Pain? Cardiologists Not Sure: MedlinePlus Health News
December 13, 2017 - Can you train yourself to develop ‘super senses’?
December 13, 2017 - Cellular self-digestion process plays role in development of autoimmune diseases
December 13, 2017 - E-cigarette use among youth leads to smoking as adults finds study
December 13, 2017 - New nanomaterial could enable new types of chemical processes in pharma, materials and chemical industries
December 13, 2017 - Another CGRP Drug Gains Ground in Migraine
December 13, 2017 - Trigger for most common form of vision loss discovered
December 13, 2017 - Study reveals link between estrogen and infertility
UVA scientists working to find end-around method to stop triple-negative breast cancer

UVA scientists working to find end-around method to stop triple-negative breast cancer

image_pdfDownload PDFimage_print

So-called “triple-negative” breast cancer is a particularly aggressive and difficult-to-treat form. It accounts for only about 10 percent of breast cancer cases, but is responsible for about 25 percent of breast cancer fatalities.

Triple-negative breast cancer earns its name because, unlike other breast cancer subtypes, its cells test negative for estrogen and progesterone receptors, as well as for a gene called HER2. Therefore, it cannot respond to therapies that inhibit cancer-growing signals that come from estrogen, progesterone and HER2. The only treatment options for triple-negative breast cancer are surgery, radiation therapy and chemotherapy, each of which cause difficult side effects and rarely lead to remission.

Triple-negative breast cancer is also highly variable from patient to patient and even among tumor cells of a single patient, making it difficult to understand and treat. Other breast cancer subtypes are homogeneous, more predictable and treatable.

University of Virginia researchers are working to study this variability and find an end-around method to stop triple-negative breast cancer, by seeking out unknown or little-understood routes toward shutting down uncoordinated growth.

“We’re interested in the variability that’s characteristic of triple-negative breast cancer,” said Kevin Janes, an associate professor of biomedical engineering. “We believe this variability gives clues to how the cancer arises, and clues to treatment possibilities that would exploit the way the tumors are regulated or misregulated as the cells communicate with each other.

“We’ve developed methods for investigating the variability of these cells, and finding targets worthy of further study, to see how they might be exploited to suppress growth of triple-negative disease. The hope is to eventually create novel medications that could stop this aggressive form of cancer by intervening in its progression, using methods we simply have not tried before. We are working hard to gain fundamental understanding of the processes that promote growth of the variable types of cells in triple-negative breast tumors. What we’re learning may inform, over the long term, the eventual development of new, targeted therapies.”

Janes is the corresponding author of a new study, conducted in collaboration with UVA pathologist Kristen Atkins, that details a possible way to reengage a tumor suppressor protein – Growth Differentiation Factor 11, or GDF11, that they found to be inactivated in triple-negative breast cancer cells. The results of the study, which combines laboratory experiments with bioinformatic analyses, are published this week in the journal Developmental Cell.

“Instead of trying to find and target hormones or genes that might promote growth of these tumor cells, as has been successful for other cancer types, we are focusing on a protein in triple-negative tumor cells that normally should inhibit abnormal cell growth, but has been disengaged,” Janes said.

Janes and his colleagues have found that GDF11 does not mature properly into a bioactive tumor suppressor, as it should normally do, but instead accumulates within cells in a “pre-active” state.

“This is an exciting realization,” Janes said, “because we now can look for ways to remobilize the GDF11 precursor and reengage its normal tumor suppressive activity wherever triple-negative cancer cells reside in the body.

“We’re still early in this investigation, but it may be a step in the right direction for getting a handle on ways to target this very difficult to treat breast cancer subtype.”

Source:

https://news.virginia.edu/content/uva-researchers-discover-new-target-triple-negative-breast-cancer

Tagged with:

About author

Related Articles